Home / Conditions / Acute Myeloid Leukemia Treatment in Delhi-NCR

Acute Myeloid Leukemia Treatment in Delhi-NCR

Acute myeloid leukemia (AML) is a type of blood cancer that begins in the bone marrow and needs to be evaluated and treated promptly. The word “acute” can sound frightening, but it only means the disease develops quickly. It does not mean there is no path forward. Treatment for AML has changed a great deal in recent years, and today it is planned around each person’s age, overall health and the genetic features of their leukemia.

This page explains AML in simple language: what it is, how it is diagnosed, what treatment options exist, and what to look for when choosing AML treatment in Delhi-NCR.

What Is Acute Myeloid Leukemia (AML)?

Acute myeloid leukemia is a cancer of the blood-forming cells in the bone marrow, in which immature cells called “blasts” multiply abnormally and crowd out healthy blood cells.

Normally, the bone marrow makes red blood cells (which carry oxygen), white blood cells (which fight infection) and platelets (which help blood clot). In AML, young white cells of the “myeloid” line do not mature properly. They build up in the marrow and spill into the blood, leaving less room for healthy cells. This is why people with AML often feel tired, catch infections easily, or bruise and bleed more than usual.

AML can occur at any age, but it becomes more common as people get older. It is different from other leukemias such as ALL, CLL and CML, and the treatment is different as well.

In short, AML is a fast-developing blood cancer, and understanding it early helps families make calm, informed decisions.

What Are the Symptoms of AML?

The common symptoms of AML are persistent tiredness, paleness, repeated infections, fever, easy bruising or bleeding, and bone or joint pain.

These happen because the marrow is making fewer healthy blood cells:

  • Low red blood cells can cause weakness, breathlessness and pale skin.
  • Low healthy white blood cells can cause frequent or lingering infections and fever.
  • Low platelets can cause nosebleeds, bleeding gums, tiny red spots on the skin or heavy bruising.

Some people also notice bone pain, swollen gums, unexplained weight loss or a feeling of fullness in the abdomen. These symptoms can also be caused by many other, far less serious conditions, so having one of them does not mean you have AML. A simple blood test is the first step to find out.

If these symptoms last more than a couple of weeks, or if there is unusual bleeding or fever, a timely blood test and consultation with a hematologist are advisable.

Reach Out for Expert Care

What Causes AML and Who Is at Risk?

AML develops when genetic changes occur in the DNA of developing blood cells, and in most people no single clear cause is found.

Certain factors are linked with a higher risk:

  • Increasing age
  • Earlier chemotherapy or radiation therapy for another cancer
  • Existing blood disorders such as myelodysplastic syndromes (MDS) or some other bone marrow conditions
  • Exposure to high levels of certain chemicals such as benzene
  • Smoking
  • Some inherited genetic conditions

Having a risk factor does not mean a person will develop AML, and many people with AML have none of them. It is also not caused by anything a patient or family did or did not do.

Knowing the possible risk factors can help doctors in assessing a person’s history, but guilt has no place in this conversation.

How Is AML Diagnosed?

AML is diagnosed through blood tests and a bone marrow examination, followed by specialised tests that study the genetic features of the leukemia.

The usual steps are:

  1. Complete blood count (CBC) and peripheral smear: shows abnormal counts and immature cells.
  2. Bone marrow aspiration and biopsy: a small sample of marrow, usually taken from the hip bone under local anaesthesia, is examined to confirm AML and measure the percentage of blasts.
  3. Flow cytometry: identifies the exact type of cells involved.
  4. Cytogenetics and molecular testing: looks for chromosomal changes and gene mutations such as FLT3, NPM1, IDH1 and IDH2. Doctors do this because these results guide the choice of treatment and help estimate how the disease may behave.
  5. Other evaluations: heart, kidney and liver checks, and infection screening, to assess how well the body can handle treatment.

These results are usually combined to place the leukemia in a risk group, which helps in planning the treatment.

A complete diagnosis, including genetic testing, is the foundation of a personalised AML treatment plan.

Why Do Genetic Tests and Risk Groups Matter in AML?

Genetic tests matter in AML because two people with the same diagnosis can have very different forms of the disease, which respond to different treatments.

Doctors commonly use international classification systems, such as the European LeukemiaNet (ELN) risk classification, to group AML as favourable, intermediate or adverse risk based on its genetic features. This is not a verdict on any one person. It is a guide that helps the treating team decide:

  • whether intensive chemotherapy or a gentler regimen is more suitable,
  • whether a targeted medicine can be added (for example, for a FLT3 or IDH mutation),
  • whether a bone marrow transplant should be planned after remission.

One special form, acute promyelocytic leukemia (APL), is treated quite differently, with a targeted combination that includes all-trans retinoic acid (ATRA) and arsenic trioxide. It needs urgent recognition, and it is generally considered one of the more treatable forms of AML.

Understanding the genetic profile turns AML treatment from “one size fits all” into a plan built around the individual.

What Are the Treatment Options for AML?

AML treatment usually includes chemotherapy, targeted therapy and, in selected patients, a bone marrow (stem cell) transplant, alongside supportive care.

The plan depends on the patient’s age, general fitness, other health conditions and the leukemia’s genetic features.

Intensive chemotherapy
For people who are fit enough, treatment often begins with “induction” chemotherapy, commonly a combination of cytarabine and an anthracycline medicine. The aim is to bring the leukemia into remission, which means no detectable leukemia cells in the marrow and recovery of blood counts. Induction is given in the hospital, because blood counts fall for some time and close monitoring is needed. After remission, further “consolidation” treatment is planned to lower the chance of the leukemia returning.

Lower-intensity treatment
For older adults or those with other health problems, gentler regimens are available. A commonly used option is a hypomethylating medicine (azacitidine) combined with venetoclax, a tablet that works by switching on the self-destruct mechanism in leukemia cells. This approach has expanded options for people who may not tolerate intensive chemotherapy.

Targeted therapy
When testing finds specific mutations, medicines aimed at them may be added. Examples include FLT3 inhibitors (such as midostaurin, quizartinib or gilteritinib) and IDH inhibitors (such as ivosidenib or enasidenib). Newer targeted agents, including menin inhibitors for certain genetic subtypes, are being studied and are entering clinical use in some countries. Availability and suitability vary, and only your doctor can advise what applies in your case.

Bone marrow transplant
In selected patients, an allogeneic stem cell transplant offers the chance of a long-term remission. This is covered in the next section.

Supportive care
Blood and platelet transfusions, infection prevention, anti-nausea medicines, nutrition support and emotional support are a core part of treatment, not an add-on.

No single treatment suits everyone, and the right combination is decided by the treating hematologist after complete evaluation.

Reach Out for Expert Care

When Is a Bone Marrow Transplant Needed for AML?

A bone marrow transplant is considered for AML when the leukemia has features that make relapse more likely, or when it has returned after treatment, and the patient is fit enough to undergo it.

In an allogeneic transplant, the patient’s diseased marrow is replaced with healthy blood-forming stem cells from a donor. These can come from a matched sibling, a matched unrelated donor, or a half-matched family member (haploidentical transplant), which has made transplant possible for many families who earlier had no fully matched donor. Beyond replacing the marrow, the donor’s immune cells can also help in controlling leftover leukemia cells.

Transplant is a major treatment with its own risks, including infections and graft-versus-host disease, so the decision is individual and made after weighing benefits and risks. Timing matters, and the discussion usually starts early, even before the first treatment is complete.

If a transplant is advised, it is planned with care, support and a clear explanation of what to expect.

What Are the Side Effects of AML Treatment and How Are They Managed?

AML treatment can cause side effects such as low blood counts, infections, nausea, hair loss, mouth sores and fatigue, and most can be managed with supportive care.

Common effects and how teams handle them:

  • Infection risk: because of low white cells, patients are monitored closely, may receive preventive medicines, and are kept in a clean, protected environment.
  • Anaemia and bleeding: managed with blood and platelet transfusions when needed.
  • Nausea and appetite changes: managed with anti-sickness medicines and dietary guidance.
  • Targeted-therapy effects: some targeted medicines need specific monitoring, for example heart rhythm checks or watching for a reaction called differentiation syndrome. The care team knows what to look for.

Side effects differ from person to person, and reporting any fever, bleeding or new symptom promptly to the care team is important.

Open communication with the care team makes treatment safer and more comfortable.

How Do Doctors Know If AML Treatment Is Working?

Doctors check treatment response through repeat blood counts and bone marrow tests, aiming for remission and, increasingly, for very low levels of leukemia known as measurable residual disease (MRD).

  • Remission: the marrow shows very few blasts, and blood counts begin to recover.
  • MRD testing: advanced tests can detect tiny numbers of leukemia cells that a microscope cannot see. MRD results help the doctor decide whether more treatment, a transplant or closer monitoring is appropriate.
  • Follow-up: after treatment, regular check-ups and blood tests continue for a period of time so that any change can be noticed early.

Remission is an encouraging milestone, and the follow-up plan keeps the focus on staying well.

What Should You Look for in AML Treatment in Delhi-NCR?

When choosing AML treatment in Delhi-NCR, it helps to look for a hospital and hematology team that can offer complete diagnostics, protected inpatient care and access to bone marrow transplant, all under one roof.

A helpful checklist for families:

  • A hematologist or hemato-oncologist with experience in leukemia care
  • In-house facilities for bone marrow examination, flow cytometry, cytogenetics and molecular testing, including MRD
  • Isolation or protected rooms for patients with low immunity
  • A round-the-clock blood bank with platelet support
  • A bone marrow transplant unit, including options for matched and haploidentical donors
  • A multidisciplinary team including nursing, nutrition, infection control and counselling
  • Clear explanation of the plan, expected duration, and estimated costs

You are always free to take a second opinion before beginning treatment. A good doctor will respect that choice.

Asking the right questions helps families feel more confident about their decision.

How Can Dr. Sanjeev Kumar Sharma Guide Patients with AML?

Dr. Sanjeev Kumar Sharma is a hemato-oncologist who has over 20 years of clinical experience in hematology and blood cancer care, and he can evaluate patients with suspected or diagnosed AML and discuss suitable treatment options.

He is the Principal Director of Hemato-Oncology & BMT at Paras Health, Gurugram. His work includes the diagnosis and treatment of blood cancers, including leukemia, and bone marrow transplant. During consultation, the focus is on understanding the patient’s reports and health, explaining the diagnosis in simple terms, and discussing the options so that the patient and family can take part in decisions.

For guidance, you may consult Dr. Sanjeev or any hematologist of your choice.

Medical Disclaimer: The information on this page is provided for educational purposes only and should not be used as a substitute for medical advice. Treatment recommendations vary from person to person and should always be based on an individual consultation and clinical evaluation by a qualified healthcare professional.

's Medical Content Team

Medical Content Grounded in Clinical Expertise

Medical information on this website is developed with a focus on clinical accuracy, current evidence, and patient understanding. Complex topics in haematology, blood disorders, and bone marrow transplantation are presented in clear, accessible language, with medical content carefully researched and reviewed to ensure it remains reliable, relevant, and useful for patients and their families.

Contact Us WhatsApp logo WhatsApp